1734 Stock Overview
Researches, develops, manufactures, and sells therapeutic drugs, health care foods, and medical beauty products in Taiwan, Mainland China, the United States, Vietnam, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Sinphar Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$36.50 |
| 52 Week High | NT$41.10 |
| 52 Week Low | NT$31.10 |
| Beta | 0.67 |
| 1 Month Change | -1.88% |
| 3 Month Change | 9.28% |
| 1 Year Change | 1.96% |
| 3 Year Change | 19.48% |
| 5 Year Change | 88.14% |
| Change since IPO | 172.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1734 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | 0.4% | 0.4% | -1.5% |
| 1Y | 2.0% | 3.8% | 25.5% |
Return vs Industry: 1734 underperformed the TW Pharmaceuticals industry which returned 3.8% over the past year.
Return vs Market: 1734 underperformed the TW Market which returned 25.5% over the past year.
Price Volatility
| 1734 volatility | |
|---|---|
| 1734 Average Weekly Movement | 3.1% |
| Pharmaceuticals Industry Average Movement | 4.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in TW Market | 8.6% |
| 10% least volatile stocks in TW Market | 2.3% |
Stable Share Price: 1734 has not had significant price volatility in the past 3 months.
Volatility Over Time: 1734's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1977 | n/a | n/a | www.sinphar.com.tw |
Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, researches, develops, manufactures, and sells therapeutic drugs, health care foods, and medical beauty products in Taiwan, Mainland China, the United States, Vietnam, and internationally. It operates through three segments: Pharmaceuticals, Healthy Food, and Other. It produces anti-cancer pharmaceuticals, such as injections, solid reagents, and hormone reagents; and tablets, soft gel capsules and powder and canned special nutrient products.
Sinphar Pharmaceutical Co.,Ltd. Fundamentals Summary
| 1734 fundamental statistics | |
|---|---|
| Market cap | NT$6.12b |
| Earnings (TTM) | NT$405.43m |
| Revenue (TTM) | NT$2.97b |
15.1x
P/E Ratio2.1x
P/S RatioIs 1734 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1734 income statement (TTM) | |
|---|---|
| Revenue | NT$2.97b |
| Cost of Revenue | NT$1.84b |
| Gross Profit | NT$1.13b |
| Other Expenses | NT$719.82m |
| Earnings | NT$405.43m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.42 |
| Gross Margin | 37.90% |
| Net Profit Margin | 13.65% |
| Debt/Equity Ratio | 54.9% |
How did 1734 perform over the long term?
See historical performance and comparison